CHMP backs approval of Chiesi's Lamzede for alpha-mannosidosis

EMA’s CHMP recommended approval of enzyme replacement therapy Lamzede velmanase alfa from Chiesi Farmaceutici S.p.A. (Parma, Italy) to treat non-neurological manifestations in patients with mild to m...